<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115800</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-2019/04/01</org_study_id>
    <nct_id>NCT04115800</nct_id>
  </id_info>
  <brief_title>Liposomal Sirolimus in Dry Eye Disease</brief_title>
  <official_title>Subconjunctival Treatment of Liposomal Sirolimus as a Treatment for Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Oftalmología Fundación Conde de Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Oftalmología Fundación Conde de Valenciana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dry eye disease is a very frequent pathology that importantly affects the quality of life of
      patients; in spite of the common use of eye lubricants to ameliorate symptoms, there is still
      a large number of patients who do not present improvement of the disease or they worsen.
      Although its etiology is varied, the imbalance of the immune system plays a substantial role
      in the development of dry eye disease. Rapamycin or sirolimus is an anti-inflammatory and
      immunomodulatory drug that has an enormous potential in ocular surface pathologies such as
      dry eye disease. The aim of the present study is to determine the effectiveness and security
      of subconjunctival application of a new formulated drug of liposomal sirolimus in patients
      with moderate and severe dry eye disease. This is a randomized placebo-controlled double
      blind clinical trial. Patients presenting data of moderate or severe dry eye disease will be
      randomized into two groups. One group will receive additional to the conventional treatment,
      subconjunctival injections of liposomal sirolimus; meanwhile the other group will receive
      subconjunctival placebo injections. After intervention the effectiveness and the security of
      the liposomal sirolimus will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Six weeks after intervention</time_frame>
    <description>The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal patients and patients with dry eye disease. The OSDI is a valid and reliable instrument for measuring dry eye disease severity (normal, mild to moderate, and sever) and effect on vision -related function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Liposomal Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Sirolimus</intervention_name>
    <description>Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease</description>
    <arm_group_label>Liposomal</arm_group_label>
    <arm_group_label>Liposomal Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with moderate or severe Dry Eye

          -  Subjects with OSDI score &gt; 22

          -  Subjects with Van Bijsterveld staining score &gt;4

          -  Subjects that accept to participate in the study

        Exclusion Criteria:

          -  Subjects with refraction surgery antecedents

          -  Subjects with ophthalmic surgery six months previous to the study

          -  Subjects with Lagophthalmos

          -  Subjects with facial paralysis antecedents

          -  Subjects with herpetic keratitis

          -  Subjects using isotretinoin

          -  Pregnant subjects

          -  Subjects in lactating period

          -  Subjects with allergy or intolerant to the drug

          -  Subjects with hepatic disorders

          -  Subjects with abnormal thoracic X rays
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alejandro Navas, MD PhD</last_name>
    <phone>+525554421700</phone>
    <phone_ext>3708</phone_ext>
    <email>alejandro.navas@institutodeoftalmologia.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Oftalmología</name>
      <address>
        <city>Mexico City</city>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonathan Garfias, MD, PhD</last_name>
      <phone>+52(55)54421700</phone>
      <phone_ext>3207</phone_ext>
      <email>yogarfias@institutodeoftalmologia.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Liposomal</keyword>
  <keyword>Subconjunctival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

